Your browser doesn't support javascript.
loading
Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia.
Samra, Kiran; Peakman, Georgia; MacDougall, Amy M; Bouzigues, Arabella; Greaves, Caroline V; Convery, Rhian S; van Swieten, John C; Jiskoot, Lize; Seelaar, Harro; Moreno, Fermin; Sanchez-Valle, Raquel; Laforce, Robert; Graff, Caroline; Masellis, Mario; Tartaglia, Maria Carmela; Rowe, James B; Borroni, Barbara; Finger, Elizabeth; Synofzik, Matthis; Galimberti, Daniela; Vandenberghe, Rik; de Mendonça, Alexandre; Butler, Chris R; Gerhard, Alexander; Ducharme, Simon; Ber, Isabelle Le; Tiraboschi, Pietro; Santana, Isabel; Pasquier, Florence; Levin, Johannes; Otto, Markus; Sorbi, Sandro; Rohrer, Jonathan D; Russell, Lucy L.
Afiliación
  • Samra K; Dementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
  • Peakman G; Dementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
  • MacDougall AM; Department of Medical Statistics London School of Hygiene and Tropical Medicine London UK.
  • Bouzigues A; Dementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
  • Greaves CV; Dementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
  • Convery RS; Dementia Research Centre Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK.
  • van Swieten JC; Department of Neurology Erasmus Medical Centre Rotterdam the Netherlands.
  • Jiskoot L; Department of Neurology Erasmus Medical Centre Rotterdam the Netherlands.
  • Seelaar H; Department of Neurology Erasmus Medical Centre Rotterdam the Netherlands.
  • Moreno F; Cognitive Disorders Unit Department of Neurology Donostia Universitary Hospital Donostia Spain.
  • Sanchez-Valle R; Neuroscience Area Biodonostia Health Research Institute San Sebastián Spain.
  • Laforce R; Alzheimer's Disease and Other Cognitive Disorders Unit Neurology Service Hospital Clínic Institut d'Investigacións Biomèdiques August Pi I Sunyer University of Barcelona Barcelona Spain.
  • Graff C; Clinique Interdisciplinaire de Mémoire Département des Sciences Neurologiques CHU de Québec, and Faculté de Médecine Université Laval, Québec City Québec Canada.
  • Masellis M; Center for Alzheimer Research Division of Neurogeriatrics Department of Neurobiology Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solnavägen Solna Sweden.
  • Tartaglia MC; Unit for Hereditary Dementias Theme Aging Karolinska University Hospital Hälsovägen Stockholm Sweden.
  • Rowe JB; Sunnybrook Health Sciences Centre Sunnybrook Research Institute University of Toronto Toronto Ontario Canada.
  • Borroni B; Tanz Centre for Research in Neurodegenerative Diseases University of Toronto Toronto Ontario Canada.
  • Finger E; Department of Clinical Neurosciences University of Cambridge Cambridge UK.
  • Synofzik M; Neurology Unit Department of Clinical and Experimental Sciences University of Brescia Piazza del Mercato Brescia Italy.
  • Galimberti D; Department of Clinical Neurological Sciences University of Western Ontario London Ontario Canada.
  • Vandenberghe R; Department of Neurodegenerative Diseases Hertie-Institute for Clinical Brain Research and Center of Neurology University of Tübingen Tübingen Germany.
  • de Mendonça A; Center for Neurodegenerative Diseases (DZNE) Tübingen Germany.
  • Butler CR; Fondazione Ca' Granda IRCCS Ospedale Policlinico Milan Italy.
  • Gerhard A; University of Milan Centro Dino Ferrari Milan Italy.
  • Ducharme S; Laboratory for Cognitive Neurology Department of Neurosciences KU Leuven Leuven Belgium.
  • Ber IL; Neurology Service University Hospitals Leuven Leuven Belgium.
  • Tiraboschi P; Leuven Brain Institute KU Leuven Leuven Belgium.
  • Santana I; Faculty of Medicine University of Lisbon Lisbon Portugal.
  • Pasquier F; Nuffield Department of Clinical Neurosciences Medical Sciences Division University of Oxford Oxford UK.
  • Levin J; Department of Brain Sciences Imperial College London London UK.
  • Otto M; Division of Neuroscience and Experimental Psychology Wolfson Molecular Imaging Centre University of Manchester Manchester UK.
  • Sorbi S; Departments of Geriatric Medicine and Nuclear Medicine University of Duisburg-Essen Duisburg Germany.
  • Rohrer JD; Department of Psychiatry McGill University Health Centre McGill University Montreal Québec Canada.
  • Russell LL; McConnell Brain Imaging Centre Montreal Neurological Institute McGill University Montreal Québec Canada.
Alzheimers Dement (Amst) ; 16(2): e12571, 2024.
Article en En | MEDLINE | ID: mdl-38623386
ABSTRACT

INTRODUCTION:

We aimed to expand the range of the frontotemporal dementia (FTD) phenotypes assessed by the Clinical Dementia Rating Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behavior and Language Domains (CDR plus NACC FTLD).

METHODS:

Neuropsychiatric and motor domains were added to the standard CDR plus NACC FTLD generating a new CDR plus NACC FTLD-NM scale. This was assessed in 522 mutation carriers and 310 mutation-negative controls from the Genetic Frontotemporal dementia Initiative (GENFI).

RESULTS:

The new scale led to higher global severity scores than the CDR plus NACC FTLD 1.4% of participants were now considered prodromal rather than asymptomatic, while 1.3% were now considered symptomatic rather than asymptomatic or prodromal. No participants with a clinical diagnosis of an FTD spectrum disorder were classified as asymptomatic using the new scales.

DISCUSSION:

Adding new domains to the CDR plus NACC FTLD leads to a scale that encompasses the wider phenotypic spectrum of FTD with further work needed to validate its use more widely. Highlights The new Clinical Dementia Rating Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behavior and Language Domains neuropsychiatric and motor (CDR plus NACC FTLD-NM) rating scale was significantly positively correlated with the original CDR plus NACC FTLD and negatively correlated with the FTD Rating Scale (FRS).No participants with a clinical diagnosis in the frontotemporal dementia spectrum were classified as asymptomatic with the new CDR plus NACC FTLD-NM rating scale.Individuals had higher global severity scores with the addition of the neuropsychiatric and motor domains.A receiver operating characteristic analysis of symptomatic diagnosis showed nominally higher areas under the curve for the new scales.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Alzheimers Dement (Amst) Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Alzheimers Dement (Amst) Año: 2024 Tipo del documento: Article